The Richmond AIDS Consortium is the clinical research arm of the VCU HIV/AIDS Center. RAC participates in a number of industry-sponsored HIV clinical trials that bring new treatments for all patients, particularly to those with drug resistant HIV and adherence issues.
RAC can assist HIV care providers with these difficult cases by combining investigational HIV medications with clinical consultation. We welcome ideas on new projects that will benefit patients living with HIV.
REPRIEVE: Randomized Trial to Prevent Vascular Events in HIV
The main purpose of this clinical trial is to see if pitavastatin can prevent heart disease and heart disease related deaths in people with HIV infection who are taking HIV medications.
In this study, people between the ages of 40 and 75 with HIV will be randomized to take the pill pitavastatin OR a placebo to see if pitavastatin can help prevent heart disease and death in people who are taking HIV medication. The study lasts approximately 72 months and you will not know if you are taking pitavastatin or a placebo. The REPRIEVE trial will enroll 6,500 people from several countries.
For more information about our research studies, contact Vicky Watson at (804) 828-3450.